Work

Low-Concentration Atropine Eye Drops in Children With Myopia and Intermittent Exotropia: The AMIXT2 Randomized Clinical Trial

Year: 2026
Type: article
Abstract: Importance: The optimal atropine concentration for myopia control in children with coexisting intermittent exotropia (IXT) remains uncertain. Objective: To compare the efficacy and safety of 0.01%, 0.02%, and 0.04% atropine eye drops in children with myopia and IXT. Design, Setting, and Participants: This single-center, double-masked, 3-arm randomized clinical trial was conducted from September 2023 to March 2026. Children aged 6 to 12 years with basic-type IXT and myopia (cycloplegic spherical equivalent [SE], -0.50 to -6.00 diopters [D]) were enrolled. Data analysis was conducted from March 2026 to July 2026. Interventions: Participants were randomized 1:1:1 to 0.01%, 0.02%, or 0.04% atropine eye drops nightly in both eyes. Main Outcomes and Measures: The primary outcome was 12-month change in cycloplegic SE. Secondary outcomes included changes in axial length (AL), exotropia conditions, binocular vision, and ocular safety parameters. Results: Among 264 randomized children (mean [SD] age, 8.4 [1.5] years; 130 female [49.2%]), 224 (84.8%) completed the 12-month assessment. Mean (SD) SE changes were -0.43 (0.50) D, -0.35 (0.51) D, and -0.18 (0.60) D with 0.01%, 0.02%, and 0.04% atropine, respectively (overall P = .001). Compared with 0.01% and 0.02% atropine, 0.04% atropine was associated with less SE progression (vs 0.01%: difference, 0.24 D; 95% CI, 0.11-0.37 D; P < .001; vs 0.02%: difference, 0.16 D; 95% CI, 0.04-0.29 D; P = .02). Mean (SD) AL changes were 0.31 (0.25) mm, 0.25 (0.23) mm, and 0.15 (0.29) mm, respectively (overall P < .001); corresponding differences for 0.04% vs 0.01% and 0.02% were -0.16 mm (95% CI, -0.22 to -0.10 mm; P < .001) and -0.10 mm (95% CI, -0.16 to -0.04 mm; P < .001). Mean (SD) near exodeviation decreased by 3.46 (5.76) prism diopters (PD), 4.84 (8.05) PD, and 6.13 (7.11) PD, respectively (overall P = .04); the reduction was greater with 0.04% vs 0.01% atropine (difference, -2.68 PD; 95% CI, -4.78 to -0.57 PD; P = .008). Study drug-related photophobia occurred in 8 (9.1%), 9 (10.2%), and 19 participants (21.6%) in the 0.01%, 0.02%, and 0.04% atropine groups, respectively; no participant discontinued treatment because of photophobia. Conclusions and Relevance: In the AMIXT2 randomized clinical trial among children with myopia and IXT, 0.04% atropine eye drops were associated with less myopia progression and axial elongation over 12 months than 0.01% or 0.02% atropine eye drops. Higher concentrations were associated with greater reductions in near magnitude of exodeviation, which warrant further investigation. Trial Registration: chictr.org.cn Identifier: ChiCTR2300075312.
Language: English
Subfield: Ophthalmology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7236619733
FWCI:
Cites: 36
Cited by:
Related to: 10